CN¥ 30.27
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substancesfermentation and purification, drug...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV
Target Price
The average target price of 688687.SS is 47 and suggests 56% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
